Ricorfotide vedotin

Overview

Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide -drug conjugate (PDC) conjugated to MMAE ( HY-15162 ), targeting Folate receptor α (FRα) and TRPV6 . Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer , breast cancer , non-small cell lung cancer , ovarian cancer , adrenocortical carcinoma and follicular dendritic cell sarcoma).

Application

Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Peptide-Drug Conjugates (PDCs) | Products > Signaling Pathways > Folate Receptor (FR) | Products > Signaling Pathways > TRP Channel

Product Information

• Catalog No.: HY-P10762
• CAS No.: 2082631-84-1
• Molecular Formula: C162H243N39O40S
• Molecular Weight: 3408.97
• Purity: 98.45%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source